The Asia Pacific IVF market to reach $4.2 billion by 2020 according to new report

The IVF market in Asia Pacific is characterized by the growth in standards of living, growing number of couples delaying parenthood due to professional commitments and trends towards financial stability. The Asia Pacific IVF market, valued at $1.3 billion in 2012, is estimated to reach $4.2 billion by 2020. Delayed pregnancy in women is one of the major driving factors of the IVF market, as the chances of conceiving lowers with age. The success rate of getting pregnant with IVF technique is higher in the age group of 35-39. Other driving factors of the IVF market are rise in infertility rate due to rise in stress levels, change in life style and fertility related diseases.

Asia in particular is facing the challenge of aging population and lower work force replacement. These trends would impact the socio-economic development and progress. Many countries in Asia Pacific which are Japan, North and South Korea, China, Vietnam, Singapore and Thailand have fertility rates that are way below the replacement fertility levels. According to the East West center study, Japan, South Korea, Singapore and Taiwan Asia’s prosperous economies have the lowest birth rate worldwide.

Taiwan has the lowest birth per women which is 0.91 (2010) when compared with South Korea (1.15), Japan (1.39) and Singapore (1.16). This trend is due to couples postponing parenthood, couples preferring few children or rather no children at all.

Countries in Asia Pacific with such lower levels of fertility have initiated innovative assistance programs to promote parenthood and provide subsidies on fertility treatments such as IVF. In addition, lower treatment cost as compared to western countries has also proved to be encouraging for the artificial reproductive treatment (ART) industry in the region. With the advancing technologies, the success ratio for ART, especially IVF, has also grown in the region. Together these factors have not only provided the region to improve on its birth rates but have also added to the growth of the medical tourism industry in the region. A number of countries have gain popularity for medical tourism, of which Malaysia, Thailand, Singapore, and India are the most preferred countries.

KEY BENEFITS

• In-depth analysis of the IVF market in 12 major country market with a cross sectional analysis of  end users segments
• Quantitative analysis of the current market and estimations through 2013-2020
• Assessment and ranking of the factors affecting the global market and impact analysis of the same
• Analysis of trends in various geographic segments that would help the companies to plan their strategies depending on the region

COVERAGE

For the purpose of better understanding of the market, the report has covered 12 country markets and has presented a cross sectional analysis of each country market for end user segments. Both revenue and number of IVF cycles performed at various end use segments is calculated based on various indicators, authentic secondary sources, government publications and primary research with leading IVF providers in each of the country. The qualitative analysis is carried out for each country market for major trends and market dynamics.

The major countries covered in this study include:

• India
• China
• Japan
• Vietnam
• Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Indonesia
• Philippines
• Singapore

Each of these country markets has been analyzed for following end user segments:

• Hospitals
• Clinics
• Surgical Centers
• Research institutes
• Banks

Know more about this report at: http://mrr.cm/Z3R

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

The global digital pathology market to reach $5.7 billion by 2020 according to new report

The digital pathology is a new technology that has digitalized the instruments used in the pathology labs for testing. The digitalization has led to the automation of the tests done during the diagnosis procedures. For example, a single digital instrument operated by a single pathologist can perform tests that were previously done using five instruments. The global digital pathology market, valued at $1.98 billion in 2012, is estimated to reach $5.7 billion by 2020. Automation in the conventional methods of pathology is the major driving force of this market, which has resulted in workflow efficiency, efficiency in analysis. Thus, resulting in fast and accurate results of the pathology tests. The other driving factors of this market are diagnosis that can be provided to patients in the remote regions and reduction in the cost of diagnosis. The cost includes procedure cost and the cost involved in delivery of the slides & data. The major limitation of the digital pathology market is the stringent regulations involved during the approval of digital pathology systems. The other limitation is the cost involved in the integration of DPS in the pathology labs. The challenges faced by the DP market are standardization and interoperability of the technology as the formats differ from region to region.

The digital pathology market is segmented into components, end users and geography. The products market consists of the Whole slide imaging (WSI), Image analysis- informatics and Storage, communication and integrated platforms. The WSI is the highest revenue generating market among the segments; however, image analysis-informatics market is expected to have the highest growth potential. The end users market is segmented into pharmaceutical research, clinical organizations and educational institutes. The pharmaceutical research is the highest revenue generating market and is also expected to have the highest growth potential. The geography market is dominated by the North American region, which is the highest revenue generating region; however, Asian market is expected to have the highest CAGR during the analysis period.

Key Benefits

• In-depth analysis of the digital pathology market, which is segmented on the basis of products, end users and geographies are discussed in the report at a greater length
• Quantitative analysis of the current market and estimations through 2013-2020, Thus helping digital pathology systems manufacturers to analyze the market
• Assessment and ranking of the factors affecting the global market and their impact  on the digital pathology market
• Study on the bargaining power of buyers and suppliers in the market, based on porter’s five force analysis. Thus helping digital pathology systems manufacturers to analyze the market
• Analysis of trends in various geographic segments that would help the companies to plan their strategies depending on the region
• SWOT and competitive analysis of the key players, which would help stakeholders to understand trends followed by their competitors and take actionable decisions.

Key Market Segments

By Components

• Whole slide imaging (WSI)
• Image analysis- informatics
• Storage, and communication and integrated platforms

By End-Users

• Pharmaceutical research
• Clinical organizations
• Educational institutes

By Geography

• North America
• Europe
• Asia
• RoW

Spanning Over 83 pages, 27 tables, 21 figures, “Global Digital Pathology Market (Components, End-Users and Geography) - Global Industry Analysis, Size, Growth Trends, Share, Opportunities and Forecast 2012 – 2020” report covering the Global Digital Pathology Market Overview, Global Digital Pathology Market By Products, Global Digital Pathology Market By End Users, Global Digital Pathology Market By Geography, Company Profiles. The report covered 10 companies - Definiens AG, Digipath, Inc., Leica Microsystems Gmbh, Ventana medical systems, Inc., Nikon Corporation, Visiopharm, Philips healthcare, Indica Labs, Inc, Omnyx LLC, 3DHISTECH, Ltd.

Know more about this report at: http://mrr.cm/Z3D

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Competitor Analysis- Cancer Vaccines, New Report Launched

The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others.

Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major pharmaceutical markets with combined 2013 sales of US$ 2,385 mln. Peptides and proteins make out 43% of clinical stage cancer vaccines, followed by dendritic cell and tumor cell (line)-based cancer vaccines with each contributing 15% to the clinical cancer vaccine pipeline. DNA- and RNA-based cancer vaccines maked out 17% of the clinical portfolio.

The report includes a compilation of currently active projects in research and development for prophylaxis and therapy of cancer. In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Company
• Product Category
• Indication
• R&D Stage and

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning Over 179 pages , “Competitor Analysis- Cancer Vaccines” report covering the Cancer Vaccines by Main Composition (Peptide-based Cancer Vaccines, Protein-based Cancer Vaccines, Idiotype Antibody-based Cancer Vaccines, DNA-based Cancer Vaccines: naked and virally vectored, RNA-based Cancer Vaccines, Virus-Like Particle (VLP)-based Cancer Vaccines, Dendritic Cell-based Cancer Vaccines, Tumor Cell and Tumor Cell Line – based Cancer Vaccines, Microorganism-based Cancer Vaccines, Other and Not Defined Cancer Vaccines), Corporate Cancer Vaccines R&D Pipelines. The report covered companies Partial List - ABIVAX, Activartis, Aduro BioTech, Advanced Cancer Therapeutics, Advaxis, Aeterna Zentaris, Agenus, Antigen Express, ApoVax, Ascend Biopharmaceuticals, Asterias Biotherapeutics, Avax Technologies, Bavarian Nordic.

See more at: http://mrr.cm/Z3h   

Find other Biotechnology Reports at : 

http://www.marketresearchreports.com/biotechnology

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter

Xenical (Obesity) - Forecast and Market Analysis to 2022, New Report Launched

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Xenical is on patent until 2018 in the US and belongs to a class of drugs known as lipase inhibitors which act on the lipase enzyme to inhibit the absorption of fat in the diet. Dietary fat that is not broken down cannot be absorbed and is eliminated, resulting in a caloric deficit for a positive effect on weight control. Xenical is the only anti-obesity drug approved by the FDA for long-term usage (up to one year) for adults and children age 12 and older.

Scope

• Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Xenical including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Xenical for the top eight countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for obesity.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Xenical performance
• Obtain sales forecast for Xenical from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, China, Brazil and Canada)

Spanning Over 49 pages, 13 tables, 1 figure, “Xenical (Obesity) - Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Xenical (orlistat), Appendix.

See more at: http://mrr.cm/Z3A

Find All Diseases Reports at: http://www.marketresearchreports.com/disease

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter

Velneperit (Obesity) - Forecast and Market Analysis to 2022, New Report Launched

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Shionogi is developing velneperit, previously known as S-2367, as an oral, once-daily, centrally-acting, small-molecule NPY5 receptor antagonist. Neuropeptide Y (NPY) is an appetite-stimulating, or orexigenic, signaling molecule that plays a role in meal initiation and the regulation of energy balance, and is believed to be especially important under conditions of food deprivation or reduced weight. Velneperit was designed to counteract elevated NPY levels, thereby promoting weight loss and continued weight-loss maintenance.

Scope

• Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on velneperit including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for velneperit for the top nine countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil, Japan and Canada

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for obesity.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of velneperit performance
• Obtain sales forecast for velneperit from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, China, Brazil, Japan and Canada)

Spanning Over 68 pages, 17 tables, 2 figures, “Velneperit (Obesity) - Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Velneperit, Appendix.

See more at: http://mrr.cm/Z3m

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter

Oblean (Obesity) - Forecast and Market Analysis to 2022, New Report Launched

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Norgine and Takeda’s Oblean (cetilistat) received Japanese regulatory approval for the treatment of obesity with complications in September 2013, less than one year after the NDA was submitted to the Ministry of Health, Labour and Welfare (MHLW). This compound was originally developed by UK-based Alizyme Therapeutics Limited and was acquired by Norgine in October 2009. Oblean has comparable efficacy to Xenical in inducing weight loss, but with a more favorable gastrointestinal side effect profile

Scope

• Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Oblean including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Oblean for the top nine countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil, Japan and Canada

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for obesity.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Oblean performance
• Obtain sales forecast for Oblean from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, China, Brazil, Japan and Canada)

Spanning Over 46 pages, 12 tables, 1 figure, “Oblean (Obesity) - Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Oblean (cetilistat), Appendix.

See more at: http://mrr.cm/Z3P

For regular industry updates subscribe to our newsletter at:

http://www.marketresearchreports.com/subscribe-to-newsletter

Empatic (Obesity) - Forecast and Market Analysis to 2022, New Report Launched

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Empatic (zonisamide SR/bupropion SR) is Orexigen Therapeutic’s second late-stage investigational medication for weight loss; the other is Contrave (bupropion/naltrexone). Empatic is an FDC of a proprietary formulation of zonisamide SR and bupropion SR. Zonisamide, an antiepileptic that is usually used to combat partial seizures, increases dopamine and serotonin neurotransmission, resulting in weight loss.

Scope

• Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Empatic including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Empatic for the top eight countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for obesity.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Empatic performance
• Obtain sales forecast for Empatic from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, China, Brazil and Canada)

Spanning Over 69 pages, 17 tables, 2 figures “Empatic (Obesity) - Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Empatic, Appendix.

See more at: http://mrr.cm/Z3M

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter

Crohn’s Disease - China Drug Forecast and Market Analysis to 2022, New Report Launched

The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Based on Publisher’s primary research, the majority of Chinese gastroenterologists follow the ACG and/or the World Gastroenterology Organization (WGO) guidelines for the management of their CD patients. In a few cases, they also refer to the local treatment guidelines. Approximately 40% of the referrals for CD patients come from PCPs, while the rest arise from their colleagues or colorectal surgeons..

Scope

• Overview of Crohn’s disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in China from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the China Crohn’s disease market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for Crohn’s disease..
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of drug performance.
• Obtain sales forecast for drugs from 2012-2022 in China.

Spanning Over 99 pages, 27 tables, 5 figures, “Crohn’s Disease - China Drug Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, China, Appendix.

See more at: http://mrr.cm/Z3n 

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter

Crohn’s Disease - Canada Drug Forecast and Market Analysis to 2022, New Report Launched

The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Based on Publisher’s primary research survey, the majority of Canadian gastroenterologists follow the AGA guidelines for the management of their CD patients. Over 65% of referrals for CD patients to a gastroenterologist come from PCPs or colorectal surgeons. The peak age for the diagnosis of CD in over 65% of cases in Canada is 17–40 years, and the diagnosis is typically confirmed by clinical evaluation and a combination of hematological, endoscopic, histological, or imaging-based investigations following the initial presenting symptoms of abdominal pain, diarrhea, and weight loss, or the more common systemic symptoms of malaise, anorexia, and fever.

Scope

• Overview of Crohn’s disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Canada from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the Canada Crohn’s disease market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for Crohn’s disease..
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of drug performance.
• Obtain sales forecast for drugs from 2012-2022 in Canada.

Spanning Over 128 pages, 37 tables, 5 figures, “Crohn’s Disease - Canada Drug Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Canada, Appendix.

See more at: http://mrr.cm/Z3s

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter

Crohn’s Disease - 5EU Drug Forecast and Market Analysis to 2022, New Report Launched

The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

In general, US and Canadian gastroenterologists follow the treatment guidelines published by the American College of Gastroenterology (ACG) and the American Gastroenterology Association (AGA), while physicians in the EU mainly rely on the European Crohn’s and Colitis Organisation (ECCO) guidelines. Outside these regions, Japanese gastroenterologists consult the guidelines published by the MHLW, while their colleagues in China and India adhere to the guidelines published by the ACG and the AGA, in addition to the guidelines issued by local medical authorities.

Scope

• Overview of Crohn’s disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in the 5 EU countries including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in the 5 EU countries from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the 5 EU Crohn’s disease market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for Crohn’s disease..
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of drug performance.
• Obtain sales forecast for drugs from 2012-2022 in the 5EU countries.

Spanning Over 168 pages, 49 tables, 9 figures, “Crohn’s Disease - 5EU Drug Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, 5 EU, Appendix.

See more at: http://mrr.cm/Z3s

Find All Diseases Reports at: http://www.marketresearchreports.com/diseases

For regular industry updates subscribe to our newsletter at:

http://www.marketresearchreports.com/subscribe-to-newsletter

Victoza (Obesity) - Forecast and Market Analysis to 2022, New Report Launched

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Victoza was approved by the FDA in 2010 as a once-daily injection to treat type 2 diabetes in adults. It is also available in the 5EU, as well as in Canada, for the same indication and use. It is not expected to be a presence in the Japanese market, as Novo Nordisk has not indicated any plans for expansion there, or in the Brazilian market, as diabetic therapies in this market are OTC.

Scope

• Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Victoza including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Victoza for the top seven countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, China and Canada

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for obesity.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Victoza performance
• Obtain sales forecast for Victoza from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, China and Canada)

Spanning over 70 pages, 17 Tables and 2 Figure  “Victoza (Obesity) - Forecast and Market Analysis to 2022” report Provide Introduction, Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Victoza (liraglutide), Appendix.

Inquiry for more information visit: http://mrr.cm/Z3d

Find All Healthcare Reports at: http://www.marketresearchreports.com/healthcare

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter

Qsymia (Obesity) - Forecast and Market Analysis to 2022, New Report Launched

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Qsymia, a novel combination of two generically available drugs, was developed by California-based Vivus. Approved by the FDA in July 2012, this once-daily, FDC therapy was one of the first drugs to receive regulatory approval for the treatment of obesity in over a decade. This combination has the two-fold intention of reducing adverse effects with a lower dosage while achieving greater weight loss than with either drug alone.

Scope

• Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Qsymia including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Qsymia from 2012 to 2022.
• Sales information covered for the US and Canada

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for obesity.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Qsymia performance
• Obtain sales forecast for Qsymia from 2012-2022 in the US and Canada

Spanning over 52 pages, 13 Tables and 1 Figure  “Qsymia (Obesity) - Forecast and Market Analysis to 2022” report Provide Introduction, Disease Overview, Disease Management, Competitive Assessment, Qsymia (phentermine-topiramate), Appendix.

Inquiry for more information visit: http://mrr.cm/Z3g

For regular industry updates subscribe to our newsletter at:

http://www.marketresearchreports.com/subscribe-to-newsletter

Contrave (Obesity) - Forecast and Market Analysis to 2022, New Report Launched

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Contrave is an investigational medication being evaluated for weight loss by San Diego, California-based Orexigen Therapeutics in partnership with Takeda Pharmaceuticals in Osaka, Japan. Takeda has already paid a $50m upfront payment to Orexigen and will be eligible to receive up to $1 billion for achieving certain regulatory and sales milestones. Takeda has obtained exclusive marketing rights for the markets in the United States, Canada and Mexico, while Orexigen maintains the right to co-promote Contrave in the US.

Scope

• Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Contrave including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Contrave for the top eight countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for obesity.
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Contrave performance
• Obtain sales forecast for Contrave from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, China, Brazil and Canada)

Spanning over 69 pages, 17 Tables and 2 Figure  “Contrave (Obesity) - Forecast and Market Analysis to 2022” report Provide Introduction, Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Contrave, Appendix.

Inquiry for more information visit: http://mrr.cm/Z3W

Find All Healthcare Reports at: http://www.marketresearchreports.com/healthcare

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter